BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
2 Nolde M, Ahn N, Dreischulte T, Rückert-Eheberg IM, Güntner F, Günter A, Gerlach R, Tauscher M, Amann U, Linseisen J, Meisinger C, Baumeister SE. The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018). Aliment Pharmacol Ther 2021;54:1033-40. [PMID: 34476821 DOI: 10.1111/apt.16565] [Reference Citation Analysis]
3 Liu Y, Zhu X, Li R, Zhang J, Zhang F. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open 2020;10:e040473. [PMID: 33243802 DOI: 10.1136/bmjopen-2020-040473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Brusselaers N, Sadr-Azodi O, Engstrand L. Proton pump inhibitors and the risk of pancreatic cancer. J Gastroenterol 2021;56:295-6. [PMID: 33527212 DOI: 10.1007/s00535-021-01761-8] [Reference Citation Analysis]
5 Fuentes-Valenzuela E, Díez Redondo P, Tejedor-Tejada J, Nájera-Muñoz R, Sánchez-Delgado L, Maroto-Martín C. [Proton-pump inhibitors treatment. Does your patient really need it?]. Semergen 2021:S1138-3593(21)00266-5. [PMID: 34728148 DOI: 10.1016/j.semerg.2021.08.002] [Reference Citation Analysis]
6 Cairat M, Al Rahmoun M, Gunter MJ, Severi G, Dossus L, Fournier A. Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Res 2020;22:118. [PMID: 33129324 DOI: 10.1186/s13058-020-01343-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rosenberg V, Tzadok R, Chodick G, Kariv R. Proton pump inhibitors long term use-trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiol Drug Saf 2021;30:1576-87. [PMID: 34453456 DOI: 10.1002/pds.5352] [Reference Citation Analysis]
8 Desbuissons G, Mercadal L. Use of proton pump inhibitors in dialysis patients: a double-edged sword? J Nephrol 2021;34:661-72. [PMID: 32710264 DOI: 10.1007/s40620-020-00808-y] [Reference Citation Analysis]
9 Giannini EG, Bodini G, Furnari M, Marabotto E. Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. Clin Gastroenterol Hepatol 2021;19:410. [PMID: 33248110 DOI: 10.1016/j.cgh.2020.04.027] [Reference Citation Analysis]
10 Kirmizi NI, Aydin V, Akici A. Utilization trend of gastric acid-suppressing agents in relation to analgesics. Pharmacoepidemiol Drug Saf 2021. [PMID: 34738287 DOI: 10.1002/pds.5381] [Reference Citation Analysis]
11 Chen F, He X, Fang B, Wang S. Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use. Drug Des Devel Ther 2020;14:5689-98. [PMID: 33380789 DOI: 10.2147/DDDT.S279302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Han N, Oh JM, Kim IW. Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems. Ther Clin Risk Manag 2021;17:877-87. [PMID: 34456568 DOI: 10.2147/TCRM.S321789] [Reference Citation Analysis]
13 Trinh NTH, Chalumeau M, Bruckner TA, Levy C, Bessou A, Milic D, Cohen R, Lemaitre M, Cohen JF. Monitoring outpatient antibiotic utilization using reimbursement and retail sales data: a population-based comparison in France, 2012-17. J Antimicrob Chemother 2021:dkab185. [PMID: 34120188 DOI: 10.1093/jac/dkab185] [Reference Citation Analysis]
14 Rückert-Eheberg IM, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, Günter A, Meisinger C, Linseisen J, Amann U, Baumeister SE. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018. Eur J Clin Pharmacol 2021. [PMID: 34877614 DOI: 10.1007/s00228-021-03257-z] [Reference Citation Analysis]
15 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
16 Muheim L, Signorell A, Markun S, Chmiel C, Neuner-Jehle S, Blozik E, Ursprung P, Rosemann T, Senn O. Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therap Adv Gastroenterol 2021;14:1756284821998928. [PMID: 33948109 DOI: 10.1177/1756284821998928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Meyer A, Fermaut M, Drouin J, Carbonnel F, Weill A. Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010-2018. PLoS One 2021;16:e0245854. [PMID: 33481904 DOI: 10.1371/journal.pone.0245854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Veremme L, Janoly-Dumenil A, Charpiat B. Curbing proton pump inhibitor overprescribing: Multifaceted strategies in an academic hospital. J Clin Pharm Ther 2021;46:1041-5. [PMID: 33629438 DOI: 10.1111/jcpt.13395] [Reference Citation Analysis]
19 Nguyen-Soenen J, Jourdain M, Fournier JP. Development of Patient Education Material for Proton Pump Inhibitor Deprescribing: A Mixed-Methods Study. Ann Pharmacother 2021;:10600280211046630. [PMID: 34553640 DOI: 10.1177/10600280211046630] [Reference Citation Analysis]
20 Bang KB. Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications? J Neurogastroenterol Motil 2021;27:448-50. [PMID: 34642265 DOI: 10.5056/jnm21177] [Reference Citation Analysis]
21 Taine M, Offredo L, Dray-Spira R, Weill A, Chalumeau M, Zureik M. Paediatric outpatient prescriptions in France between 2010 and 2019: A nationwide population-based study: Paediatric outpatient prescriptions in France, 2010 to 2019. Lancet Reg Health Eur 2021;7:100129. [PMID: 34557839 DOI: 10.1016/j.lanepe.2021.100129] [Reference Citation Analysis]
22 Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis 2020;52:862-8. [PMID: 32505566 DOI: 10.1016/j.dld.2020.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]